Table 2.
Baseline Clinical Characteristics of Patients Receiving CT or Non-CT in the Different EF Categories Stratified According to Activity Levels
| HFrEF | HFmrEF | HFpEF | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Independent outdoor walking |
Not independent outdoor walking |
Independent outdoor walking |
Not independent outdoor walking |
Independent outdoor walking |
Not independent outdoor walking |
|||||||
| CT | Non-CT | CT | Non-CT | CT | Non-CT | CT | Non-CT | CT | Non-CT | CT | Non-CT | |
| No. subjects | 137 | 63 | 44 | 64 | 39 | 39 | 23 | 24 | 138 | 180 | 78 | 189 |
| Age (years) | 67.7± 12.0* |
73.1± 11.3 |
81.7± 8.7 |
83.9± 7.2 |
70.8± 10.9 |
73.7± 8.8 |
81.9± 8.3 |
83.4± 8.7 |
74.2± 10.1 |
75.2± 9.9 |
84.4± 7.2 |
86.0± 8.1 |
| Male sex (%) | 70.8 | 63.5 | 45.5 | 51.6 | 69.2 | 59.0 | 21.7 | 41.7 | 55.1 | 53.3 | 26.9 | 33.3 |
| Comorbidities (%) | ||||||||||||
| History of HF | 60.6* | 76.2 | 70.5 | 73.4 | 56.4 | 48.7 | 60.9 | 58.3 | 47.1 | 44.4 | 55.1 | 58.7 |
| Coronary artery disease |
32.9 | 42.9 | 40.9 | 42.2 | 35.9 | 41.0 | 30.4 | 33.3 | 29.0* | 17.8 | 23.1 | 14.8 |
| Cardiomyopathy | 27.0 | 27.0 | 22.7 | 20.3 | 12.8 | 18.0 | 8.7 | 8.3 | 10.1 | 11.1 | 12.8 | 7.9 |
| Hypertension | 70.1* | 41.3 | 72.7* | 46.8 | 84.6 | 69.2 | 78.3 | 54.2 | 79.7* | 60.6 | 80.8* | 58.7 |
| Diabetes | 37.2 | 38.1 | 38.6 | 37.5 | 46.2 | 41.0 | 47.8 | 29.2 | 37.7* | 26.1 | 32.1 | 25.4 |
| Atrial fibrillation | 30.7 | 39.7 | 47.7 | 51.6 | 28.2 | 46.2 | 56.5 | 66.7 | 54.4 | 45.0 | 42.3 | 41.3 |
| CKD | 44.5 | 52.4 | 70.5 | 59.4 | 38.5 | 51.3 | 60.9 | 54.2 | 44.2 | 46.7 | 52.6 | 50.8 |
| History of stroke | 2.2* | 12.7 | 25.0 | 21.9 | 15.4 | 7.7 | 17.4 | 37.5 | 3.6 | 7.8 | 14.1 | 13.2 |
| LVEF (%) | 29.2± 6.7 |
31.1± 7.4 |
32.4± 7.1 |
30.9± 6.6 |
45.1± 2.3 |
45.3± 2.4 |
45.1± 2.6 |
45.5± 2.2 |
64.4± 8.2 |
64.9± 8.3 |
65.5± 9.8 |
65.5± 8.8 |
|
eGFR (mL/min/1.73 m2) |
53.6 [41.4– 64.5] |
46.6 [34.5– 64.9] |
41.1 [31.8– 51.2] |
41.4 [31.1– 59.0] |
53.9 [42.2– 63.2] |
47.1 [35.7– 70.7] |
42.0 [29.7– 57.3] |
44.3 [29.6– 63.0] |
49.7 [37.2– 64.6] |
50.7 [36.7– 65.1] |
46.3 [31.8– 66.9] |
45.0 [32.8– 56.2] |
| BNP (pg/dL) | 202 [90– 428] |
342 [129– 558] |
392 [261– 693] |
443 [183– 679] |
206 [75– 491] |
282 [93– 560] |
347 [135– 516] |
312 [109– 688] |
156 [60– 298] |
152 [61– 292] |
222 [108– 458] |
173 [93– 403] |
| Medications (%) | ||||||||||||
| Diuretic | 91.2 | 95.2 | 97.7 | 93.8 | 84.6 | 82.1 | 87.0 | 83.3 | 78.3* | 65.5 | 80.8 | 72.5 |
| MRA | 19.7 | 20.6 | 15.9 | 21.9 | 20.5 | 25.6 | 26.1 | 16.7 | 13.8 | 12.8 | 10.3 | 16.9 |
| Calcium channel blocker |
13.9* | 4.8 | 11.4 | 12.5 | 15.4 | 20.5 | 21.7 | 8.3 | 20.3 | 23.9 | 24.4 | 23.8 |
| Oral inotropic agent |
9.5 | 15.9 | 2.3* | 21.9 | 2.6 | 7.7 | 0.0 | 8.3 | 2.9 | 1.7 | 3.9 | 6.4 |
| Digitalis | 2.9 | 7.9 | 4.6 | 9.4 | 5.1 | 7.7 | 4.4 | 12.5 | 8.7* | 2.2 | 2.6 | 2.7 |
Unless indicated otherwise, data are presented as the mean±SD or as the median [interquartile range]. *P<0.05 compared with the non-CT group. Abbreviations as in Table 1.